Published in Neuro Oncol on April 03, 2012
Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol (2014) 3.01
Ophthalmological assessment of children with neurofibromatosis type 1. Eur J Pediatr (2013) 1.99
Applications of optical coherence tomography in pediatric clinical neuroscience. Neuropediatrics (2015) 1.44
Ganglion cell layer-inner plexiform layer thickness and vision loss in young children with optic pathway gliomas. Invest Ophthalmol Vis Sci (2014) 1.07
Impact of vision loss among survivors of childhood central nervous system astroglial tumors. Cancer (2016) 1.06
Handheld optical coherence tomography during sedation in young children with optic pathway gliomas. JAMA Ophthalmol (2014) 1.00
Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology (2013) 0.96
Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol (2016) 0.91
Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs (2013) 0.88
NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1. Hum Mol Genet (2016) 0.87
Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth. Neuro Oncol (2014) 0.87
The impact of coexisting genetic mutations on murine optic glioma biology. Neuro Oncol (2014) 0.81
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A (2014) 0.81
Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol (2016) 0.81
Intra- and inter-visit reproducibility of ganglion cell-inner plexiform layer measurements using handheld optical coherence tomography in children with optic pathway gliomas. Am J Ophthalmol (2014) 0.80
Longitudinal Change of Circumpapillary Retinal Nerve Fiber Layer Thickness in Children With Optic Pathway Gliomas. Am J Ophthalmol (2015) 0.80
Vision specific quality of life in children with optic pathway gliomas. J Neurooncol (2013) 0.79
Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1. Neuro Oncol (2013) 0.78
Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1. Neurology (2014) 0.78
Detection of tumor progression in optic pathway glioma with and without neurofibromatosis type 1. Neuro Oncol (2013) 0.77
Optic glioma and precocious puberty in a girl with neurofibromatosis type 1 carrying an R681X mutation of NF1: case report and review of the literature. BMC Endocr Disord (2015) 0.77
Role of visual evoked potentials in the assessment and management of optic pathway gliomas in children. Doc Ophthalmol (2013) 0.77
Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1. Am J Med Genet A (2016) 0.77
Correlation of optical coherence tomography parameters with clinical and radiological progression in patients with symptomatic optic pathway gliomas. Graefes Arch Clin Exp Ophthalmol (2013) 0.77
Investigation of retinal nerve fiber layer thickness in patients with neurofibromatosis-1. Jpn J Ophthalmol (2014) 0.76
Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1. Neurology (2016) 0.76
Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology. J Exp Med (2016) 0.75
The role of the immune system in neurofibromatosis type 1-associated nervous system tumors. CNS Oncol (2016) 0.75
CNS Tumors in Neurofibromatosis. J Clin Oncol (2017) 0.75
Neuroimaging of phakomatoses: overview and advances. Pediatr Radiol (2015) 0.75
Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol (2007) 2.75
Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg (1997) 2.23
Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol (2011) 1.80
Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol (1997) 1.47
High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol (2002) 1.45
Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy--results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol (2003) 1.33
Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol (2001) 1.31
Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur J Cancer (2006) 1.22
Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro Oncol (2007) 1.20
Retracted Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol (1995) 1.19
Long-term outcome in children with gliomas of the anterior visual pathway. Pediatr Neurol (2003) 1.18
Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology (2004) 1.17
Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. J Neurosurg (1991) 1.11
When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. Eur J Pediatr (2000) 1.08
Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol (2002) 1.07
Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up. Cancer (1995) 1.06
Natural history and outcome of optic pathway gliomas in children. Pediatr Blood Cancer (2009) 1.04
Natural history and clinical management of optic pathway glioma. Br J Neurosurg (2003) 1.03
Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis. AJNR Am J Neuroradiol (2001) 1.03
Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: an update. Ann Neurol (1988) 0.99
Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1. Pediatr Blood Cancer (2010) 0.97
Optic pathway glioma: outcome and prognostic factors in a surgical series. Childs Nerv Syst (2006) 0.96
Visual outcome following chemotherapy for progressive optic pathway gliomas. Pediatr Blood Cancer (2011) 0.92
Long-term visual outcome in patients with anterior visual pathway gliomas. J Neuroophthalmol (2001) 0.91
Visual pathway glioma: an erratic tumour with therapeutic dilemmas. Arch Dis Child (1997) 0.91
Visual improvement despite radiologically stable disease after treatment with carboplatin in children with progressive low-grade optic/thalamic gliomas. J Pediatr Hematol Oncol (2001) 0.88
Optico-hypothalamic glioma: an analysis of 16 cases. Childs Nerv Syst (1993) 0.86
Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. Eur J Cancer (2010) 0.85
Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. J AAPOS (2010) 0.84
MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis. Br J Radiol (2001) 0.82
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology (2013) 8.25
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol (2002) 8.03
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
Subtypes of medulloblastoma have distinct developmental origins. Nature (2010) 5.94
Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci (2008) 5.89
The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol (2009) 5.86
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol (2008) 5.55
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology (2006) 4.72
International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res (2002) 4.27
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol (2012) 4.00
New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst (2006) 3.90
Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol (2006) 3.68
Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst (2009) 3.52
Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol (2010) 3.51
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain (2011) 3.48
Neurofibromatosis 2. Curr Opin Neurol (2003) 3.46
Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol (2002) 3.37
Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell (2011) 3.11
Neurofibromatosis type 1 revisited. Pediatrics (2009) 3.06
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res (2007) 3.05
Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol (2014) 3.01
Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature (2012) 2.96
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol (2010) 2.96
Postoperative cerebellar mutism syndrome following treatment of medulloblastoma: neuroradiographic features and origin. J Neurosurg Pediatr (2010) 2.92
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol (2013) 2.82
Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol (2012) 2.79
Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol (2005) 2.76
Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol (2007) 2.75
Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res (2004) 2.75
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol (2007) 2.73
Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol (2006) 2.71
Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol (2002) 2.65
Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell (2008) 2.65
Intraoperative performance and postoperative outcomes of endocapsular ring implantation in pediatric eyes. J Cataract Refract Surg (2008) 2.56
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol (2011) 2.53
Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology (2012) 2.48
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med (2002) 2.44
Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol (2007) 2.44
The King-Devick test and sports-related concussion: study of a rapid visual screening tool in a collegiate cohort. J Neurol Sci (2011) 2.43
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology (2013) 2.43
Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med (2002) 2.39
Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol (2013) 2.34
Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol (2012) 2.34
Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. J Neurosurg (2006) 2.31
Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res (2003) 2.30
Neurocognitive status in long-term survivors of childhood CNS malignancies: a report from the Childhood Cancer Survivor Study. Neuropsychology (2009) 2.29
Pediatric idiopathic intracranial hypertension. Surv Ophthalmol (2007) 2.24
Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol (2009) 2.23
Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. JAMA Neurol (2013) 2.22
Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A (2008) 2.22
Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol (2008) 2.20
Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study. J Clin Oncol (2004) 2.15
Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer (2003) 2.11
Change in neurocognitive functioning after treatment with cranial radiation in childhood. J Clin Oncol (2004) 2.07
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology (2013) 2.06
Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol (2002) 2.05
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2012) 2.04
Laser pointer visual field screening. J Neuroophthalmol (2003) 2.03
Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res (2005) 2.02
Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy. Leuk Lymphoma (2007) 2.01
Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol (2011) 2.01
Morphology of the foramen magnum in syndromic and non-syndromic brachycephaly. Childs Nerv Syst (2015) 1.96
Medulloblastoma in childhood: new biological advances. Lancet Neurol (2007) 1.93
Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell (2007) 1.92
Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell (2009) 1.92
Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol (2008) 1.92
Reference range for cerebrospinal fluid opening pressure in children. N Engl J Med (2010) 1.89
Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol (2012) 1.88
Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol (2012) 1.88
Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development (2005) 1.85
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol (2011) 1.85
Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol (2009) 1.85
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol (2010) 1.83
Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions. Am J Ophthalmol (2006) 1.81
Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet (2007) 1.80
Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol (2011) 1.80
Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res (2006) 1.80
Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol Genet Metab (2012) 1.79
Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer (2010) 1.76
Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol (2010) 1.74
Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. Ann Neurol (2003) 1.72
Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood. J Clin Oncol (2005) 1.71
Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res (2007) 1.69
Diffuse intrinsic brainstem tumors in neonates. Report of two cases. J Neurosurg Pediatr (2008) 1.69
Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25. Am J Ophthalmol (2006) 1.66
Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes. Cancer Res (2007) 1.65